B Cell Targeted Therapy in MS:

New Possibilities

This presentation is not intended for physicians practicing in the US

NP/OCRE/1509/0022i
 Chair’s Welcome

Dr. Amado
Centro Internacional de Restauración Neurológica
Cuba
This presentation contains information about a
non-authorised product(s)/investigational
drug(s)
Reminders

• Please switch your mobile phones to

silent

• Use the electronic key pads provided

for all questions
and comments throughout
the presentations

• At the end of the meeting, please hand

in your completed evaluation forms to
the hostesses
 Despite progress in treating MS, many important unmet needs
remain

Current situation Unmet need

High-efficacy treatments with the

A large proportion of MS patients
experience disease activity
despite treatment with DMTs1  potential to impact
neurodegeneration and promote
remyelination2

For some treatments, there may A tolerable high-efficacy

be a compromise between treatment with a favourable
efficacy and safety3 benefit/risk balance4

The attributes of currently Treatments with an MOA that

available treatments may present supports improved persistence
adherence challenges5-8 and adherence9

DMT, disease-modifying treatment; MOA, mechanism of action.

1. Rotstein DL, et al. JAMA Neurol 2015;72:152–8. 2. Williams A. Neurodegener Dis Manag 2015;5:49–59.
3. Markowitz CE. Am J Manag Care 2010;16(suppl):S211–8. 4. Hartung HP, et al. Expert Rev Neurother 2011;11:351–62.
5. Lugaresi A. Expert Opin Drug Deliv 2009;6:995–1002. 6. Patti F. Patient Prefer Adherence 2010;4:1–9.
7. Reynolds MW, et al. Curr Med Res Opin 2010;26:663–74. 8. Dionne CA, et al. CMSC 2015; Poster DX19
9. Miller AE, Rhoades RW. Curr Opin Neurol 2012;25(suppl):S4–10.
 Emerging therapies in MS
Study phase MS disease
Generic name Target
(RoA)1 course1
Daclizumab CD252 III (SC) RRMS
III (IV) RMS
Ocrelizumab CD202
III (IV) PPMS
Inhibits cytokines and lymphocyte migration into III (Oral) RMS
Laquinimod2
the CNS2 II (Oral) PPMS
Siponimod Sphingosine 1-phosphate 1/5 receptors2 III (Oral) SPMS
Ponesimod Sphingosine 1-phosphate 1 receptor3 III (Oral) RMS
II (IV) RRMS
Ofatumumab CD202
II (SC) RRMS
ATX-MS-1467 Reduces T-cell response to myelin4 II (ID)5 RMS
Secukinumab IL-17A2 II (IV) RRMS
Ibudilast Phosphodiesterases, leukotrienes, NO synthesis2 II (Oral) PMS
BIIB033 LINGO-16 II (IV) RRMS or SPMS
Vatelizumab VLA-27 II (IV) RRMS

CNS, central nervous system; ID, intradermal; IL, interleukin; IV, intravenous; NO, nitric oxide; PMS, progressive MS; PPMS, primary progressive MS;
RoA, route of administration; RMS, relapsing MS; RRMS, relapsing remitting MS; SC, subcutaneous; SPMS, secondary progressive MS.

1. ClinicalTrials.gov. https://www.clinicaltrials.gov/. Accessed 3 September 2015; 2. Ali R, et al. Drugs 2013;73:625–50. 3. Subei AM, Cohen JA. CNS Drugs 2015;29:565–75; 4.
Streeter HB, et al. Neurol Neuroimmunol Neuroinflamm 2015;2:e93. 5. EU Clinical Trials Register. https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002916-28/LV.
Accessed 6 October 2015. 6. Tran JQ, et al. Neurol Neuroimmunol Neuroinflamm 2014;1: e18. 7. Genzyme press release. http://news.genzyme.com/press-release/genzyme-
announces-enrollment-first-patient-phase-ii-vatelizumab-trial-relapsing-remitt. Accessed 2 October 2015.
Agenda

Time Topic Speaker

5 min Chair’s welcome Dr. Amado
10 min The role of B cells in MS Dr. Fernando Gracia
New possibilities with B cell
20 min Dr. Fernando Gracia
targeted therapy
15 min Panel discussion: Dr. Amado
Evolving treatment options and
strategies
5 min Close Dr. Amado
Meet the faculty
 The Role of B Cells in MS

Dr. Fernando Gracia

(pendiente incluir Presentación del Doctor)
Panel Discussion

Moderated by:
Dr. Amado
Closing Remarks

Dr. Amado
 B Cell Targeted Therapy in MS:
New Possibilities

NP/OCRE/1509/0022i